CARA - Why Is Itch-Focused Cara Therapeutics Stock Trading Lower Today? | Benzinga
Cara Therapeutics Inc (NASDAQ: CARA) announced the outcome from the dose-finding Part A of the KIND 1 study evaluating the efficacy and safety of oral difelikefalin as adjunct therapy to topical corticosteroids (TCS) for moderate-to-severe pruritus in adult patients with atopic dermatitis (AD).
Oral difelikefalin as an adjunct to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone, resulting in the company's decision to discontinue its clinical program in pruritus associated with atopic dermatitis.
The company's Korsuva (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
Cara ...